Article

Single-Dose and Multiple-Dose Pharmacokinetics and Safety of Telbivudine After Oral Administration in Healthy Chinese Subjects

Peking Union Medical College Hospital, Beijing, People's Republic of China.
The Journal of Clinical Pharmacology (Impact Factor: 2.47). 10/2006; 46(9):999-1007. DOI: 10.1177/0091270006290623
Source: PubMed

ABSTRACT The pharmacokinetics of telbivudine, an L-nucleoside with potent activity against hepatitis B virus, was assessed in 42 healthy Chinese volunteers. Subjects were assigned to receive a single oral dose of 200, 400, or 800 mg telbivudine or repeat doses of 600 mg/d. Telbivudine was absorbed rapidly and exhibited dose-related plasma exposure. After reaching maximum concentration (C(max)) at a median time of 2.0 to 2.5 hours, plasma disposition of the drug was biphasic with a mean terminal half-life ranging from 39.4 to 49.1 hours. Telbivudine accumulated slightly after repeat doses, and steady state was reached after 5 to 6 consecutive doses of 600 mg/d. The mean steady-state C(max) and area under the plasma concentration-time curve over the dosing interval of telbivudine 600 mg were 3.7 microg/mL and 26.1 microg x h/mL, respectively. Cumulative urinary excretion of telbivudine over 32 hours represented 24.4% of the administered dose, with a mean renal clearance of 6.6 L/h. Telbivudine was well tolerated in the studied dose range in healthy Chinese subjects, with no pattern of dose-related clinical or laboratory adverse events.

Download full-text

Full-text

Available from: Pei Hu, Jun 24, 2015
0 Followers
 · 
150 Views
  • Source
    Hospital pharmacy 04/2007; 42(4):345-355. DOI:10.1310/hpj4204-345
  • Gut 02/2008; 57(1):105-24. DOI:10.1136/gut.2005.077891 · 13.32 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Three hundred and fifty million people worldwide are estimated to be chronically infected with hepatitis B virus. 15%-40% of these subjects will develop cirrhosis, liver failure or hepatocellular carcinoma during their life. Approved drugs for chronic hepatitis B treatment include: standard interferon-alpha 2b, pegylated interferon-alpha 2a, lamivudine, adefovir dipivoxil, and entecavir. Unfortunately, these agents are not effective in all patients and are associated with distinct side effects. Interferons have numerous side effects and nucleoside or nucleotide analogues, which are well tolerated, need to be used for prolonged periods, even indefinitely. Telbivudine is a novel, orally administered nucleoside analogue for use in the treatment of chronic hepatitis B and it was approved by the FDA in late 2006. In contrast to other nucleoside analogues, Telbivudine has not been associated with inhibition of mammalian DNA polymerase with mitochondrial toxicity. Telbivudine has demonstrated potent activity against hepatitis B with a significantly higher rate of response and superior viral suppression compared with lamivudine, the standard treatment, and adefovir. Telbivudine has been generally well tolerated, with a low adverse effect profile, and at its effective dose, no dose-limiting toxicity has been observed. The aim of this review is to evidence the pharmacodynamic and pharmacokinetic characteristics of this drug and to evaluate its efficacy and tolerance.
    Anti-Infective Agents in Medicinal Chemistry (Formerly ?Current Medicinal Chemistry - Anti-Infective Agents) 09/2008; 7(4):245-248. DOI:10.2174/187152108785908866